Cidofovir Anhydrous 113852-37-2 Antiviral
Intlawulo:T/T, L/C
Imvelaphi yeMveliso:eTshayina
Indawo yokuthumela ngenqanawa:Beijing/Shanghai/Hangzhou
Umthamo wemveliso:1kg/ngenyanga
Umyalelo(MOQ):1g
Ixesha lokukhokhela:Iintsuku zokusebenza ezi-3
Imeko yokugcina:Igcinwe kwindawo epholileyo neyomileyo, ivalwe kwaye igcinwe kude nokukhanya.
Ipakethe imathiriyeli:ibhotile, ibhotile
Ubungakanani bepakethi:1g/ibhodlela, 5/ibhotile, 10g/ibhotile, 50g/ibhotile, 500g/ibhotile
Ulwazi ngokhuseleko:UN 2811 6.1/ PG 3
Intshayelelo
I-Cidofovir dihydrate yidihydrate yohlobo oluyi-anhydrous ye-cidofovir.I-nucleoside analogue, yi-antiviral etofwayo esetyenziselwa unyango lwe-cytomegalovirus (CMV) retinitis kwizigulana ze-AIDS.Inendima njengeyeza le-antiviral kunye ne-antineoplastic agent.
Inkcazo (kwimigangatho yendlu)
| Izinto | Iinkcukacha |
| Imbonakalo | Imhlophe ukuya kumgubo omhlophe wekristale |
| Ukuchongwa
| I-Infrared Spectroscopy |
| Ixesha lokugcinwa kweSampuli yesisombululo sihambelana neso sisombululo soMgangatho, njengoko sifunyenwe kwi-Assay. | |
| Intsalela kwi-Ignition | ≤0.5% |
| Ukungcola Okuphilayo
| Cidofovir diol analoga≤0.15% |
| Ikhompawundi enxulumene neCidofovir A ≤0.15% | |
| Ikhompawundi enxulumene neCidofovir B ≤0.15% | |
| I-analog yeCidofovir uracilb ≤0.15% | |
| Bromocidofovirc≤0.15% | |
| Nawuphi na umntu ongachazwanga ukungcola ≤0.10% | |
| Ubumdaka bubonke ≤1.0% | |
| Ucoceko lwe-Enantiomeric | ≤1.0% |
| Iimvavanyo zoBalo lweMicrobialkunye novavanyo lweeMicroorganisms ezichaziweyo | Ubalo lulonke lwebhaktiriya ye-aerobic yi-NMT 102cfu/g.Itotali yokungunda kunye nokubalwa kwegwele yi-NMT 101cfu/g. |
| Ukumiselwa kwamanzi | ≤0.5% |
| pH | 2.5-4.5 |
| Isivavanyi | 98.0% -102.0%, kwisiseko se-anhydrous |
